Pharmaceuticals, Biotechnology and Life Sciences
TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today the acceptance of a new manuscript…
inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets CAMBRIDGE, England–(BUSINESS WIRE)–PhoreMost, the UK-based…
Phase 1 trial scheduled for early 2020 will be first CAR-T cell therapy clinical trial to employ SMARTvector technology Horizon…
– Updated results from the Phase IIIb/IV PROPEL Study show that pharmacokinetic (PK)-driven dosing may be used to achieve FVIII…
– Updated results from the Phase IIIb/IV PROPEL Study show that pharmacokinetic (PK)-driven dosing may be used to achieve FVIII…
– Encorafenib combinations (encorafenib + binimetinib + cetuximab together = encorafenib Triplet; encorafenib + cetuximab together = encorafenib Doublet) showed…
The first two patients treated at the 3e13 vg/kg dose level rapidly achieved normal, sustained Factor VIII (FVIII) levels with…
Eric Bruno has joined Dentsply Sirona as Senior Vice President of the North America Regional Commercial Organization. He is responsible…
Global Medical cannabis leader expands dispensary footprint to Gainesville, one of Florida’s most densely populated metropolitan areas and provides update…
DUBLIN–(BUSINESS WIRE)–The “Cholera Vaccines Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering.…